Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27895202 | 0.91 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL27912353 | 0.89 | SLC6A2 (0.34) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| Propionic Acid SCHEMBL72834 | 0.87 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL1746181 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL1035508 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL21069936 | 0.82 | — | — | |
| SCHEMBL21070848 | 0.82 | — | — | |
| SCHEMBL6689960 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL3945988 | 0.80 | SLC6A4 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL11652607 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4304818-A | POLYISOCYANURATE-OXAZOLIDONES FROM POLYISOCYANATE AND POLYEPOXIDE | HITACHI, LTD. (JP) | 1981-12-08 | — | — | US | claimed |
| US-3979365-A | FROM A POLYOXAZOLIDINE PREPOLYMER AND POLYISOCYANATE | HITACHI, LTD. (JA) | 1976-09-07 | — | — | US | claimed |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| CN-101824008-B | Preparation method of N, N-dimethyl aminopropyl morpholine | ZHANGJIAGANG CITY DAWEI ASSISTANTS INDUSTRY CO LTD | 2012-05-30 | — | — | CN | disclosed |
| EP-2424865-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2393813-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010127237-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| CN-101824008-A | Preparation method of N,N-dimethyl aminopropyl morpholine | ZHANGJIAGANG CITY DAWEI ASSISTANTS INDUSTRY CO LTD | 2010-09-08 | — | — | CN | disclosed |
| WO-2010091067-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
| US-4304818-A | POLYISOCYANURATE-OXAZOLIDONES FROM POLYISOCYANATE AND POLYEPOXIDE | HITACHI, LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4070416-A | POLYFUNCTIONAL ISOCYANATES AND EPOXIDES, ISOCYANURATE-OXAZOLIDOLE POLYMERS | HITACHI, LTD. (JA) | 1978-01-24 | — | — | US | disclosed |
| US-3979365-A | FROM A POLYOXAZOLIDINE PREPOLYMER AND POLYISOCYANATE | HITACHI, LTD. (JA) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | BRD4, BRD3, BRDT | SLC6A2 4250/4885SLC6A3 3952/4885SLC6A4 4522/4885 |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | SLC6A2 4250/4885SLC6A3 3952/4885SLC6A4 4522/4885 |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | SLC6A2 4595/4885SLC6A3 4461/4885SLC6A4 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.